9 reports of this reaction
1.9% of all CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL reports
#10 most reported adverse reaction
EXPOSURE VIA INHALATION is the #10 most commonly reported adverse reaction for CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL, manufactured by Procter & Gamble Manufactura S de RL de CV. There are 9 FDA adverse event reports linking CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL to EXPOSURE VIA INHALATION. This represents approximately 1.9% of all 485 adverse event reports for this drug.
Patients taking CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL who experience exposure via inhalation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EXPOSURE VIA INHALATION is a less commonly reported adverse event for CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL, but still significant enough to appear in the safety profile.
In addition to exposure via inhalation, the following adverse reactions have been reported for CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL:
EXPOSURE VIA INHALATION has been reported as an adverse event in 9 FDA reports for CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
EXPOSURE VIA INHALATION accounts for approximately 1.9% of all adverse event reports for CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL, making it a notable side effect.
If you experience exposure via inhalation while taking CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.